GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Institutional Ownership

InnoCare Pharma (HKSE:09969) Institutional Ownership : 7.88% (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, InnoCare Pharma's institutional ownership is 7.88%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, InnoCare Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, InnoCare Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.


InnoCare Pharma Institutional Ownership Historical Data

The historical data trend for InnoCare Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Institutional Ownership Chart

InnoCare Pharma Historical Data

The historical data trend for InnoCare Pharma can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 6.35 6.34 6.39 6.34 6.30 6.75 7.80 7.82 7.81 7.88

InnoCare Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


InnoCare Pharma (HKSE:09969) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines